<?xml version="1.0" encoding="UTF-8"?>
<p id="Par35">Our prevalence of HIV/HBV co-infection (13.1%) fall within the range observed in a previous study in the sub-Saharan region (0â€“28.4%) [
 <xref ref-type="bibr" rid="CR27">27</xref>]. The HIV/HBV co-infection estimate is higher than that among other population groups in the Mozambique where there was an estimated 4.9% of youths HIV infected in Maputo [
 <xref ref-type="bibr" rid="CR13">13</xref>] and 9.1% of untreated HIV-infected adults [
 <xref ref-type="bibr" rid="CR14">14</xref>]. The hepatitis B vaccine was only introduced into the Mozambican national vaccine program for children in 2001 [
 <xref ref-type="bibr" rid="CR28">28</xref>]. Although the HBV vaccine is not widely available for the adult population, anti-retroviral therapy (ART) based-on tenofovir (TDF), lamivudine (3TC) and efavirenz (EFV) has dual treatment benefits for both HBV and HIV infections [
 <xref ref-type="bibr" rid="CR9">9</xref>, 
 <xref ref-type="bibr" rid="CR12">12</xref>, 
 <xref ref-type="bibr" rid="CR27">27</xref>].
</p>
